116 related articles for article (PubMed ID: 3817281)
1. Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients.
Alvisi V; D'Ambrosi A; Loponte A; Pazzi P; Greco A; Zangirolami A; Palazzini E
J Int Med Res; 1987; 15(1):49-56. PubMed ID: 3817281
[TBL] [Abstract][Full Text] [Related]
2. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.
Corazza GR; Ventrucci M; Strocchi A; Sorge M; Pranzo L; Pezzilli R; Gasbarrini G
J Int Med Res; 1988; 16(4):312-6. PubMed ID: 3169375
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin in the treatment of chronic hepatic encephalopathy.
Puxeddu A; Quartini M; Massimetti A; Ferrieri A
Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
[TBL] [Abstract][Full Text] [Related]
5. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
Miglio F; Valpiani D; Rossellini SR; Ferrieri A
Curr Med Res Opin; 1997; 13(10):593-601. PubMed ID: 9327194
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Pedretti G; Calzetti C; Missale G; Fiaccadori F
Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.
Bucci L; Palmieri GC
Curr Med Res Opin; 1993; 13(2):109-18. PubMed ID: 8325041
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
Williams R; Bass N
Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin for the treatment of hepatic encephalopathy.
Mantry PS; Munsaf S
Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
[TBL] [Abstract][Full Text] [Related]
13. Review of rifaximin as treatment for SIBO and IBS.
Pimentel M
Expert Opin Investig Drugs; 2009 Mar; 18(3):349-58. PubMed ID: 19243285
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.
Di Stefano M; Malservisi S; Veneto G; Ferrieri A; Corazza GR
Aliment Pharmacol Ther; 2000 May; 14(5):551-6. PubMed ID: 10792117
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.
Lauritano EC; Gabrielli M; Scarpellini E; Ojetti V; Roccarina D; Villita A; Fiore E; Flore R; Santoliquido A; Tondi P; Gasbarrini G; Ghirlanda G; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2009; 13(2):111-6. PubMed ID: 19499846
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin may have a dramatic effect on hepatic encephalopathy.
Lamb C; Reddy AV
Clin Med (Lond); 2012 Oct; 12(5):489-90. PubMed ID: 23101155
[TBL] [Abstract][Full Text] [Related]
17. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
18. Ammonia abolishers: antibiotics for hepatic encephalopathy.
Felicilda-Reynaldo RF
Medsurg Nurs; 2012; 21(3):173-5; quiz 176. PubMed ID: 22866441
[No Abstract] [Full Text] [Related]
19. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
Kok B; Foxton MR; Clough C; Shawcross DL
Hepatology; 2013 Oct; 58(4):1516-7. PubMed ID: 23471844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
